Pharmacokinetics of Bilobalide, Ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans

Phytotherapy Research

Volumn 24, Issue 3, 2010, Pages 445-450

  Woelkart, Karin ^a   Feizlmayr, Elisabeth ^a   Dittrich, Peter ^a   Beubler, Eckhard ^b   Pinl, Fritz ^c   Suter, Andy ^d   Bauer, Rudolf ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Sanatorium Hansa   (Austria)

^d A Vogel Bioforce AG   (Switzerland)

Author keywords

Bilobalide; Ginkgo biloba; Ginkgolide A; Ginkgolide B; Humans; Pharmacokinetics

Indexed keywords

BILOBALIDE; GERIAFORCE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GINKGO BILOBA; HUMAN; HUMAN EXPERIMENT; ION MONITORING; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPENTANES; FEMALE; FURANS; GINKGO BILOBA; GINKGOLIDES; HUMANS; LACTONES; MALE; MASS SPECTROMETRY; PHYTOTHERAPY; PLANT EXTRACTS; TABLETS; YOUNG ADULT;

GINKGO BILOBA;

EID: 77349104616     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3074     Document Type: Article

References (13)

1. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H. 2002. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 9(Suppl 3): 1-33.
2. Biber A. 2003. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 36(Suppl. 1): 32-37.
3. ESCOP (European Scientific Cooperative on Phytotherapy). 2003. Monograph Ginkgo folium. In ESCOP Monographs - The Scientific Foundations for herbal medicinal products (2. Completely revised and expanded edition), ESCOP (ed.). Thieme Publishing House, Stuttgart, Germany and New York, USA; 178-210.
4. Fourtillan JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, Biber A. 1995. Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie 50: 137-144.
5. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M. 2001. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41: 492-499.
6. Kressmann S, Biber A, Wonnemann M, Schug B, Blume HH, Müller WE. 2002. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol 54: 1507-1514.
7. Lang F, Stumpf H. 1999. Consideration on future pharmacopoeial monographs for plant extracts. Pharmeuropa V 11: 268-275.
8. Loew D, Kaszkin M. 2002. Approaching the problem of bio-quivalence of herbal medicinal products. Phytother Res 16: 705-711.
9. Morant J, Ruppanner H. 2002. Arzneimittel-Kompendium der Schweiz 2003/04. Basel: Publikumsausgabe; 577-587, 581, 1010-011, 1307-1308, 1321, 1329.
10. Nieder M. 1991. Pharmakokinetik der Ginkgo-Flavonole im Plasma. Münch Med Wochenschr 133 (Suppl.): 61-62.
11. Smith PF, Maclennan K, Darlington CL. 1996. The neuroprotective properties of the Ginkgo biloba leaf: A review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 50: 131-139.
12. Xie J, Ding C, Ge Q, Zhou Z, Zhi X. 2008. Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and ist application to the pharmacokinetic study of Ginkgo biloba extract in rats. J Chromatogr B 864: 87-94.
13. Zhao Y, Sun Y, Li C. 2008. Simultaneous determination of Ginkgo flavonoids and terpenoids in plasma: Ammonium formate in LC mobile phase enhancing electrospray ionization efficiency and capacity. J Am Soc Mass Spectrom 19: 445-449.